4/A: CytoMed Therapeutics Director Buys Shares
Insider Transaction (Form 4/A)
Chee Kong Choo, a Director and 10% owner of CytoMed Therapeutics Ltd, purchased 200,000 shares of common stock on July 14, 2026 for $1.50 per share.
Summary
- Open-market purchase: acquired 100,000 ORDINARY SHARES OF CYTOMED THERAPEUTICS LIMITED at $1.50 ($150,000) on July 14, 2026; holds 530,324 after (Direct).
- Open-market purchase: acquired 100,000 ORDINARY SHARES OF CYTOMED THERAPEUTICS LIMITED at $1.50 ($150,000) on July 20, 2026; holds 630,324 after (Direct).
Sentiment
Score: 8
Explanation: StockSavvy.ai views this as a bullish signal: an insider made an open-market purchase of $300,000, committing personal capital to the stock.
Insider Transactions
Chee Kong Choo — Director, 10% owner
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-14 | Open-market purchase | ORDINARY SHARES OF CYTOMED THERAPEUTICS LIMITED | 100,000 | $2 | $150.0K | 530,324 |
| 2026-07-20 | Open-market purchase | ORDINARY SHARES OF CYTOMED THERAPEUTICS LIMITED | 100,000 | $2 | $150.0K | 630,324 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-14 | Open-market purchase (100,000 shares) |
| 2026-07-20 | Open-market purchase (100,000 shares) |
Keywords
insider transaction, Form 4/A, GDTC, CytoMed Therapeutics Ltd, bullish, Chee Kong Choo
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.